Refine by
Clinical Stage Articles & Analysis
840 news found
BC Platforms has embedded NVIDIA accelerated computing into BC Mosaic, its trusted research environment, enabling faster GPU-powered analytics and AI-led analyses across clinical, multi-omics, and real-world data to support precision medicine and accelerated drug development.NVIDIA integration in BC MosaicNVIDIA technology is now natively available within BC Mosaic, providing ...
(Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. ...
ByKalaris
Synaptive’s integrated suite of products – bridging MRI, surgical planning, navigation, and robotic visualization – delivers patient-centric information with automated efficiency across all stages of clinical interventions. About Unity Health Toronto Unity Health Toronto is a health care network and university -affiliated teaching and ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. ...
According to University of Arizona clinical professor of medicine and dream specialist, Rubin Naiman, PhD, the two key components of good sleep quality are non-REM and REM sleep. Unfortunately, sleep-tracking technology cannot measure rapid eye movement or REM sleep. This is the stage most closely associated with dreaming. As a result, we can’t always ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") ...
Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth ...
” The clinical course of CKD in people with T1D is characterized by an increased urinary albumin excretion rate, which is a first sign of kidney damage and may progress to macroalbuminuria and decrease in eGFR in later stages. ...
ByBayer AG
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. ...
“Tris Pharma has a robust and expanding portfolio of clinically proven, best-in-class ADHD therapies,” said Englese. “I believe there is tremendous opportunity to help enhance the company’s commercial success by further expanding the availability of this growing portfolio, which offers a range of delivery and treatment options for both adults and children ...
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple ...
BAY 2927088 is a reversible small molecule inhibitor that is currently being evaluated in a first-in-human, Phase 1 clinical trial in non-small cell lung cancer (NSCLC) patients with mutations in epidermal growth factor receptors (EGFR & HER2) including exon20 insertions and point mutations. For the first time, Bayer will present the design of the clinical ...
ByBayer AG
The antibody was transferred to Aulos Bioscience, a Biolojic spinoff that is now conducting clinical trials in Australia and is currently recruiting patients, with hopes of reporting interim data later this year. ...
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. Araris stands to make an impact in the ADC space and I am honored to be a part of the ...
In these positions he was responsible for the Discovery, Pharmacology, Toxicology and DMPK (Drug Metabolism & Pharmacokinetics) activities in close collaboration with CMC (chemistry, manufacturing, control), Clinical Development as well as Regulatory Affairs ensuring smooth and successful project transition from research into early and late-stage ...
Used a celiac disease specific patient reported outcomes (PRO) instrument to demonstrate that latiglutenase also protects against adverse clinical effects of gluten consumption. First-time clinical-trial use of a gluten-immunogenic peptide (GIP) in urine assay to demonstrate ~95% elimination of gluten in the stomach (p < 0.0001) by latiglutenase. ...